IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

Steven A. Rosenberg, Claude Sportès, Mojgan Ahmadzadeh, Terry J. Fry, Lien T. Ngo, Susan L. Schwarz, Maryalice Stetler-Stevenson, Kathleen E. Morton, Sharon A. Mavroukakis, Michel Morre, Renaud Buffet, Crystal L. Mackall, Ronald E. Gress

Research output: Contribution to journalArticlepeer-review

325 Scopus citations


Lymphopenia is a serious consequence of HIV infection and the administration of cancer chemotherapeutic agents. Although growth factors can be administered to patients to increase circulating neutrophils, there is no effective method to stimulate CD8 lymphocyte production in humans, in vivo. This report is the first to describe the administration of recombinant interleukin-7 to humans and demonstrates the ability of this cytokine to mediate selective increases in CD4 and CD8 lymphocytes along with a decrease in the percentage of CD4 T-regulatory cells. These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia.

Original languageEnglish (US)
Pages (from-to)313-319
Number of pages7
JournalJournal of Immunotherapy
Issue number3
StatePublished - May 2006


  • Human lymphocytes
  • Interleukin-7
  • Lymphopoiesis
  • Regulatory T cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'IL-7 administration to humans leads to expansion of CD8<sup>+</sup> and CD4<sup>+</sup> cells but a relative decrease of CD4<sup>+</sup> T-regulatory cells'. Together they form a unique fingerprint.

Cite this